Bristol Myers Squibb Co. BMY, -0.41% on Friday reported fourth-quarter results that beat analysts’ expectations, helped by portfolio stalwarts like the blood thinner Eliquis as well as strong growth among newer drugs. The drugmaker reported fourth-quarter net income of $1.762 billion, or 87 cents per share, down from$2.022 billion, or 95 cents per share, in the year-earlier period. Adjusted earnings per share came to $1.70, down 7$1.55. Revenue to ...